Investor Presentaiton
Novo Nordisk Annual Report 2023
Introducing Novo Nordisk
Strategic Aspirations Risks
Management
Consolidated statements
Additional information
DIABETES VALUE MARKET SHARE (%)
... GLP-1 -- Insulin
-Total diabetes
60
54.9%
54.8%
52.7%
50.4%
50
44.3%
43.8%
44.6%
43.9%
40
33.8%
31.9%
29.3%
30.1%
30
20
2020
2021
2022
2023
Source: IQVIA MAT, Nov 2023.
DIABETES SALES (DKK billion)
200
Sales as reported Growth at CER
14%
160
13%
8%
120
80
40
29%
0
2020
2021
2022
2023
DIABETES
Strengthening diabetes leadership
with strong GLP-1-based product growth
We have extended our leadership in diabetes care and
increased our value market share by 1.9 percentage points
to 33.8% in 2023, fuelled by strong uptake of the GLP-1-based
products OzempicⓇ and Rybelsus® in both North America and
International Operations.
OzempicⓇ is now the world's biggest-selling diabetes medicine.
Available as a once-weekly injection, it is contributing to a
major shift in treatment for type 2 diabetes. At the same time,
our oral GLP-1-based therapy, Rybelsus®, is gaining ground by
offering patients with type 2 diabetes an intervention without
injections. Demand for these two products has grown to
unprecedented levels, helping to generate record sales growth
despite supply constraints and a decline in demand for the
first-generation GLP-1-based product VictozaⓇ.
Although competition is increasing, Novo Nordisk remains
the market leader in the GLP-1 market with a value share of
54.8%, broadly steady compared to 2022 where our value
share stood at 54.9%.
The high demand for our GLP-1-based medicines is partly
fuelled by a growing understanding of the importance of the
class among healthcare professionals, patients and payers.
This includes a recognition that certain GLP-1-based therapies
are not only highly effective options for controlling blood
sugar levels, but may also offer significant benefits in terms
of reducing weight and cardiovascular risks - positive effects
now reflected in international treatment guidelines.
Despite declining sales of insulin in key markets, reflecting
both pricing pressures and lower volumes in some
geographies, Novo Nordisk's insulin value market share
remains little changed from 12 months earlier, at 43.9%,
compared to 44.6% in 2022.
Across International Operations, insulin is still an important
and growing segment, although insulin sales in China have
been adversely impacted since the introduction of Volume
Based Procurement in mid-2022. The US has also experienced
a decline in overall volumes and a decrease in realised prices
due to channel/payer mix and higher rebates.
Nevertheless, in a global diabetes market driven by high
GLP-1 growth, we are uniquely positioned to maintain and
strengthen our leadership in this sector and have already
met our target of securing value market share of at least
one-third by 2025.
31
31View entire presentation